NINDNational Industries Group Holding (stock symbol)
NINDNon-Inflammatory Neurological Disease
References in periodicals archive ?
Contract Line Item Number: Ninds medicinal chemistry consultant support services
This work was supported by the NINDS (NS091618-01) and the Department of Defense (W81XWH-13-2-0095).
Since our initial NIH BPN award in 2011, AMRI has provided discovery chemistry services to NINDS and its private sector BPN members on 15 drug candidate programs, and two of these programs have advanced to the stage where a pre-clinical candidate has been declared, with a third candidate pending.
In the NINDS studies, the protocols dictated that treatment start within 3 hours of onset of symptoms, and within 90 min for half the patients.
Kovach, President and CEO of Lixte, said, "Studies with the research team at the Molecular Pathogenesis Unit, Surgical Neurology Branch, NINDS, identified a biomarker that appears to be preferentially targeted by novel anti-cancer drugs currently being evaluated by NINDS and Lixte as new treatments for human brain tumors.
What will the neuroscience research landscape look like in 15 years, and how can NINDS best contribute?
Here, visitors can learn more about what clinical trials really are; those who wish to participate in a clinical trial can choose from an extensive list of neurological conditions, from ADHD to Zellweger syndrome, to see what research is in progress or coming up at the NINDS and elsewhere across the country.
Thirteen new genetic markers, 11 this year alone, have been identified since the striking discovery six years ago of the first marker for the HD gene by NINDS grantee Dr.
AMRI has been collaborating with NINDS since 2005 on novel treatments for spinal muscular atrophy, a degenerative neuromuscular disease.
This study was supported by the Intramural Research Programs at the NINDS and the National Cancer Institute, the National Multiple Sclerosis Society, and the Conrad N.
Kovach, the lead presenter and President and CEO of Lixte, said that the company and SNB, NINDS are continuing to develop LB-1 and other compounds for the treatment of human brain cancers.
The National Institute of Neurological Disorders and Stroke (NINDS) has set aside a total of $2,250,000, in addition to funds available for applications sent in response to this PA that score within the NINDS payline (see NINDS Funding Strategy http://www.